在一项大型临床试验中,PROs与临床医生报告的不良事件:来自POLARIX第三阶段研究的发现
Carrie Thompson1, Marek Trněný2, Franck Morschhauser3
1Mayo Clinic College of Medicine, Rochester, Minnesota, United States.
Blood
|September 25, 2025
概括
在POLARIX研究中发现,与R-CHOP相比,Polatuzumab vedotin加R-CHOP在扩散性大B细胞淋巴瘤 (DLBCL) 患者中改善了生活质量. 患者报告的结果突出显示了症状经历,补充了临床医生的数据.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 患者报告的结果
背景情况:
- 扩散性大B细胞淋巴瘤 (DLBCL) 对症状变化和治疗对健康相关生活质量 (HRQoL) 的影响提出了复杂的挑战.
- 第3阶段的POLARIX研究先前在未经治疗的DLBCL中确定了波拉图祖马布维多丁加R-CHOP (Pola-R-CHP) 与R-CHOP的无进展生存期 (PFS).
研究的目的:
- 在POLARIX研究中使用患者报告结果 (PRO) 仪器评估与健康相关的生活质量 (HRQoL).
- 描述患者体验,并将PRO与临床医生报告的不良事件 (AE) 进行比较.
主要方法:
- 使用PRO仪器分析HRQoL,淋巴瘤和胃肠道 (GI) 症状的基线变化.
- 在874名可评估患者中,患者报告的症状与临床医生报告的副作用的比较.
主要成果:
- 在PRO和临床医生报告的副作用之间观察到显著的不一致性,患者报告症状发生率较高.
- 波拉-R-CHP和R-CHOP都显示了HRQoL和淋巴瘤症状的快速和持续改善.
- 胃肠道症状在手臂之间是相似的,在治疗后得到解决;在总体健康状况,疲劳和功能方面有所改善.
结论:
- 患者报告的结果对于全面评估治疗疗效和耐受性至关重要,它补充了临床医生报告的数据.
- 波拉-R-CHP可能为患者报告的HRQoL在以前未经治疗的DLBCL中建立一个新的基准,提高患者的体验.
更多相关视频
相关概念视频
Clinical Trials
10.1K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
10.1K
Clinical Trials: Overview
4.6K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.6K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
407
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
407
Pharmacovigilance
1.6K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.6K
Hazard Ratio
561
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
561
Bioavailability Study Design: Healthy Subjects Versus Patients
144
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
144


